Comparison between ticagrelor and clopidogrel in myocardial infarction patients with high bleeding risk- A report from the SWEDEHEART registry.
Jonathan TjerkaskiTomas JernbergJoakim AlfredssonDavid ErlingeStefan K JamesBertil LindahlMoman Aladdin MohammadElmir OmerovicDimitrios VenetsanosKarolina Elisabeth SzummerPublished in: European heart journal. Cardiovascular pharmacotherapy (2023)
We observed no difference in NACE when comparing ticagrelor and clopidogrel in HBR patients. Moreover, we found no statistically significant interactions between bleeding risk and the comparative effectiveness of clopidogrel and ticagrelor in a larger population of MI patients.
Keyphrases
- acute coronary syndrome
- percutaneous coronary intervention
- end stage renal disease
- antiplatelet therapy
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- st segment elevation myocardial infarction
- prognostic factors
- atrial fibrillation
- heart failure
- st elevation myocardial infarction
- coronary artery disease
- patient reported outcomes